Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Thyroid Gland Carcinoma”

116 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 116 results

Not applicableUnknownNCT04858867
What this trial is testing

Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)

Who this might be right for
Differentiated Thyroid Cancer
Leiden University Medical Center 12
Early research (Phase 1)Study completedNCT00667641
What this trial is testing

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Who this might be right for
Breast CancerColorectal CancerHead and Neck Cancer+6 more
University of Medicine and Dentistry of New Jersey 16
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Study completedNCT00176748
What this trial is testing

Treatment for Patients With Metastatic Thyroid Cancer

Who this might be right for
Thyroid Cancer
University of Michigan Rogel Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT02702388
What this trial is testing

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Who this might be right for
Thyroid Cancer
Eisai Inc. 241
Testing effectiveness (Phase 2)Study completedNCT01270321
What this trial is testing

Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Emory University 42
Testing effectiveness (Phase 2)Study completedNCT00094055
What this trial is testing

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Pfizer 60
Testing effectiveness (Phase 2)UnknownNCT04554680
What this trial is testing

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Who this might be right for
Thyroid Cancer
National University Hospital, Singapore 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT02465060
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder Carcinoma+49 more
National Cancer Institute (NCI) 6,452
Not applicableLooking for participantsNCT06443866
What this trial is testing

I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

Who this might be right for
Thyroid CancerRAI-Refractory Thyroid Cancer
Miami Cancer Research Center, Inc. 50
Not applicableStudy completedNCT05507775
What this trial is testing

Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma

Who this might be right for
Non-Medullary Thyroid Carcinoma
Radboud University Medical Center 8
Not applicableStudy completedNCT02764554
What this trial is testing

Post-Marketing Surveillance of Lenvima in Korean Patients

Who this might be right for
Differentiated Thyroid Carcinoma (DTC)
Eisai Korea Inc. 132
Testing effectiveness (Phase 2)Active Not RecruitingNCT03914300
What this trial is testing

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Gland CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland Carcinoma+6 more
National Cancer Institute (NCI) 11
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Not applicableActive Not RecruitingNCT04970134
What this trial is testing

Spanish Study for Molecular Characterization of Thyroid Carcinoma

Who this might be right for
Differentiated Thyroid CarcinomaMedullary Thyroid Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello 150
Testing effectiveness (Phase 2)Study completedNCT01208051
What this trial is testing

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Who this might be right for
Refractory Differentiated Thyroid Gland CarcinomaRefractory Thyroid Gland Follicular CarcinomaRefractory Thyroid Gland Hurthle Cell Carcinoma+2 more
National Cancer Institute (NCI) 127
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439292
What this trial is testing

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 44
Not applicableStudy completedNCT04821336
What this trial is testing

Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance

Who this might be right for
Thyroid Cancer
Institut Claudius Regaud 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401
What this trial is testing

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Who this might be right for
Solid TumorsCNS Tumors
Hoffmann-La Roche 69
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Next Page